By Fineline Cube ImmuneOnco Biopharmaceuticals (HKG: 1541) announced that its drug IMM0306 has received Investigational New Drug (IND) clearance from the U.S. FDA to conduct a Phase Ib/II clinical trial for the treatment of systemic lupus erythematosus (SLE) — marking the U.S. clinical debut of the world’s first CD47- and CD20-targeted bispecific molecule to enter clinical development.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. FDA |
| Approval Type | Investigational New Drug (IND) clearance |
| Product | IMM0306 |
| Trial Phase | Phase Ib/II |
| Indication | Systemic lupus erythematosus (SLE) |
| Sponsor | ImmuneOnco Biopharmaceuticals (HKG: 1541) |
| Announcement Date | 21 Aug 2026 |
| Novelty | First-in-class — first CD47/CD20 bispecific molecule in clinical development globally |
Drug Profile & Mechanism
- Molecule: Bispecific molecule independently developed by the Group
- Dual Targets: Cluster of Differentiation 47 (CD47) and Cluster of Differentiation 20 (CD20)
- First-in-Class Status: World’s first CD47- and CD20-targeted bispecific molecule to enter clinical development
- Rationale: Combines B-cell depletion via CD20 with CD47 pathway modulation in a single molecule — a differentiated approach versus standalone anti-CD20 antibodies currently used in autoimmune disease
Clinical Pipeline Across Autoimmune Indications
Multiple clinical studies of IMM0306 are currently underway in China across a portfolio of B-cell–driven autoimmune diseases:
| Indication | Status |
|---|---|
| Systemic lupus erythematosus (SLE) | Multiple studies underway in China; Phase Ib/II now IND-cleared in the U.S. |
| IgG4-related disease (IgG4-RD) | Clinical studies underway in China |
| Primary Sjögren’s syndrome (pSS) | Clinical studies underway in China |
Market Impact & Outlook
- Global Expansion Milestone: FDA IND clearance extends IMM0306’s development from China into the U.S., the largest and most commercially consequential market for lupus therapeutics.
- First-in-Class Differentiation: As the only CD47/CD20 bispecific in the clinic worldwide, IMM0306 holds an uncontested mechanistic niche in SLE, where existing targeted options remain limited beyond belimumab and anifrolumab.
- Multi-Indication Optionality: Concurrent development across SLE, IgG4-RD and pSS creates several near-term catalyst paths — a single readout in any indication could validate the platform for the others.
- Next Milestones: Investors will watch for first U.S. patient dosing, Phase Ib safety and dose-optimization data, and potential regulatory designations as the program advances.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory timelines and commercial potential of IMM0306. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, and competitive dynamics in autoimmune disease therapeutics.-Fineline Info & Tech